NZ598063A - Gram-positive bacteria specific binding compounds - Google Patents

Gram-positive bacteria specific binding compounds

Info

Publication number
NZ598063A
NZ598063A NZ598063A NZ59806310A NZ598063A NZ 598063 A NZ598063 A NZ 598063A NZ 598063 A NZ598063 A NZ 598063A NZ 59806310 A NZ59806310 A NZ 59806310A NZ 598063 A NZ598063 A NZ 598063A
Authority
NZ
New Zealand
Prior art keywords
seq
sequence
gram
specific binding
positive bacteria
Prior art date
Application number
NZ598063A
Other languages
English (en)
Inventor
Tim Beaumont
Mark Jeroen Kwakkenbos
Eric J Brown
John Hiroshi Morisaki
Wouter L W Hazenbos
Sanjeev Mariathasan
Kimberly Kajihara
Yi Xia
Original Assignee
Genentech Inc Aimm Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc Aimm Therapeutics B V filed Critical Genentech Inc Aimm Therapeutics B V
Priority to NZ616921A priority Critical patent/NZ616921A/en
Publication of NZ598063A publication Critical patent/NZ598063A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
NZ598063A 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds NZ598063A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ616921A NZ616921A (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
EP09165558 2009-07-15
PCT/NL2010/050456 WO2011008092A2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Publications (1)

Publication Number Publication Date
NZ598063A true NZ598063A (en) 2014-07-25

Family

ID=41467048

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598063A NZ598063A (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds
NZ616921A NZ616921A (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ616921A NZ616921A (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Country Status (24)

Country Link
US (9) US20110020323A1 (enExample)
EP (1) EP2454284B1 (enExample)
JP (3) JP6192294B2 (enExample)
KR (1) KR101832201B1 (enExample)
CN (2) CN102666583B (enExample)
AR (1) AR077756A1 (enExample)
AU (2) AU2010271582B2 (enExample)
BR (1) BR112012000953A8 (enExample)
CA (1) CA2768204A1 (enExample)
DK (1) DK2454284T3 (enExample)
EA (1) EA031447B1 (enExample)
ES (1) ES2673323T3 (enExample)
HK (1) HK1222418A1 (enExample)
HU (1) HUE038277T2 (enExample)
IL (3) IL217497A (enExample)
MX (1) MX350234B (enExample)
NZ (2) NZ598063A (enExample)
PL (1) PL2454284T3 (enExample)
SG (2) SG177653A1 (enExample)
SI (1) SI2454284T1 (enExample)
TR (1) TR201809128T4 (enExample)
TW (2) TW201610153A (enExample)
WO (1) WO2011008092A2 (enExample)
ZA (2) ZA201200363B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
WO2012072814A1 (en) * 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
CN102559733A (zh) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
EP2975054A4 (en) * 2013-03-12 2016-11-23 Zenyaku Kogyo Kk ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
MX369758B (es) * 2013-05-31 2019-11-20 Genentech Inc Anticuerpos anti-acido teicoico de pared y conjugados.
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
PE20160715A1 (es) * 2013-05-31 2016-08-01 Genentech Inc Anticuerpos frente a acidos teicoicos de pared y conjugados
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
EP3572425A1 (en) 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
DK3099709T3 (da) 2014-01-31 2020-02-03 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af stabile antistoffer
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
MX2017007231A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
TW201730211A (zh) * 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (ko) * 2019-11-14 2021-09-13 연세대학교 산학협력단 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
US20250064921A1 (en) * 2021-12-28 2025-02-27 Cz Biohub Sf, Llc Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501418A (ja) 1994-06-07 1998-02-10 ザ・ロックフェラー・ユニバーシティ 黄色ぶどう球菌の表面蛋白
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
EP0807185B9 (en) * 1995-01-30 2002-12-11 Lunamed AG Antitumor preparations containing a lipoteichoic acid from steptococcus
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
EP2330192A1 (en) 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
IL141639A (en) 1998-08-31 2005-12-18 Inhibitex Inc Multicomponent vaccines
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
WO2002072600A2 (en) 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004025416A2 (en) 2002-09-13 2004-03-25 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
WO2004110367A2 (en) * 2003-05-29 2004-12-23 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
KR20070104590A (ko) * 2005-01-10 2007-10-26 나비 바이오파마슈티컬즈 스타필로코쿠스 아우레우스 감염을 치료하는 방법
US8475798B2 (en) 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
AU2007221321B2 (en) 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
CN101302504B (zh) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 一种抗体亲和层析纯化溶葡萄球菌酶的方法
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
US20090162379A1 (en) 2007-10-01 2009-06-25 Magnus Hook Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
CA2713241C (en) 2008-01-31 2022-10-04 Timothy Foster Treatment of microbial infections
WO2010005513A2 (en) 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
AU2010272505B2 (en) 2009-07-16 2015-09-17 Glaxosmithkline Biologicals S.A. Treatment of infections

Also Published As

Publication number Publication date
ES2673323T3 (es) 2018-06-21
SG10201704269RA (en) 2017-06-29
US9927428B2 (en) 2018-03-27
AU2016250398A1 (en) 2016-11-17
JP6192294B2 (ja) 2017-09-06
NZ616921A (en) 2015-06-26
US20160222096A1 (en) 2016-08-04
KR20120065326A (ko) 2012-06-20
US9266943B2 (en) 2016-02-23
TR201809128T4 (tr) 2018-07-23
US20120157665A1 (en) 2012-06-21
IL217497A0 (en) 2012-02-29
CN105440133A (zh) 2016-03-30
AU2010271582A1 (en) 2012-03-01
ZA201200363B (en) 2014-06-25
AU2010271582A2 (en) 2013-05-16
SI2454284T1 (en) 2018-07-31
US20170067880A1 (en) 2017-03-09
KR101832201B1 (ko) 2018-02-28
MX350234B (es) 2017-08-30
TWI502068B (zh) 2015-10-01
BR112012000953A2 (pt) 2016-11-22
US20160168232A9 (en) 2016-06-16
US20130261293A1 (en) 2013-10-03
CN102666583A (zh) 2012-09-12
BR112012000953A8 (pt) 2017-12-26
PL2454284T3 (pl) 2018-09-28
AR077756A1 (es) 2011-09-21
US9688745B2 (en) 2017-06-27
JP2018134089A (ja) 2018-08-30
WO2011008092A2 (en) 2011-01-20
US20150376266A1 (en) 2015-12-31
US20130253175A1 (en) 2013-09-26
CN102666583B (zh) 2015-11-25
US20110020323A1 (en) 2011-01-27
WO2011008092A3 (en) 2011-05-26
JP2012533293A (ja) 2012-12-27
TW201610153A (zh) 2016-03-16
EP2454284A2 (en) 2012-05-23
AU2010271582B2 (en) 2016-07-28
US9090677B2 (en) 2015-07-28
US9458228B2 (en) 2016-10-04
WO2011008092A4 (en) 2011-07-07
EA201390967A1 (ru) 2014-01-30
IL217497A (en) 2015-11-30
HUE038277T2 (hu) 2018-10-29
US9399673B2 (en) 2016-07-26
AU2016250398B2 (en) 2018-09-27
US20180292391A1 (en) 2018-10-11
ZA201400644B (en) 2015-10-28
SG177653A1 (en) 2012-02-28
EP2454284B1 (en) 2018-04-11
IL238074A (en) 2016-06-30
TW201107470A (en) 2011-03-01
JP2016135771A (ja) 2016-07-28
HK1222418A1 (zh) 2017-06-30
US20140235828A1 (en) 2014-08-21
EA031447B1 (ru) 2019-01-31
IL242207A0 (en) 2015-11-30
DK2454284T3 (en) 2018-07-02
CA2768204A1 (en) 2011-01-20
US8617556B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ599405A (en) Targeted binding agents against b7-h1
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
NZ714516A (en) Human antibodies to clostridium difficile toxins
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ602020A (en) Anti-cd40 antibodies
NZ610091A (en) Antibodies
NZ610734A (en) Human antibodies to the glucagon receptor
NZ595792A (en) Antibodies specific to cadherin-17
NZ595235A (en) Compositions and methods for increasing muscle growth
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
MX2018009498A (es) Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1.
WO2009086539A3 (en) Treatment and prophylaxis of amyloidosis
NZ600348A (en) Anti-c5a binding moieties with high blocking activity
NZ705848A (en) Anti-cd38 antibodies
NZ607710A (en) 4-1bb binding molecules
NZ597314A (en) Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
TW200720289A (en) Antibodies against CCR5 and uses thereof
SI2579894T1 (en) CGRP PROTITELESA

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GENENTECH, INC., US

Free format text: OLD OWNER(S): AIMM THERAPEUTICS B.V.; GENENTECH, INC.; TIM BEAUMONT; MARK JEROEN KWAKKENBOS; ERIC J BROWN; JOHN HIROSHI MORISAKI; WOUTER L W HAZENBOS; SANJEEV MARIATHASAN; KIMBERLY KAJIHARA; YI XIA

Owner name: AIMM THERAPEUTICS B.V., NL

Free format text: OLD OWNER(S): AIMM THERAPEUTICS B.V.; GENENTECH, INC.; TIM BEAUMONT; MARK JEROEN KWAKKENBOS; ERIC J BROWN; JOHN HIROSHI MORISAKI; WOUTER L W HAZENBOS; SANJEEV MARIATHASAN; KIMBERLY KAJIHARA; YI XIA

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2017 BY AJ PARK

Effective date: 20141208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2018 BY THOMSON REUTERS

Effective date: 20170621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY THOMSON REUTERS

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2020 BY THOMSON REUTERS

Effective date: 20190620

LAPS Patent lapsed